


# MedChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

## Prekinamycin and an Isosteric-Isoelectronic Analogue Exhibit Comparable Cytotoxicity Towards K562 Human Leukemia Cells

Glenn L. Abbott,<sup>a</sup> Xing Wu,<sup>b</sup> Zhufeng Zhao,<sup>c</sup> Lei Guo,<sup>c</sup> Vladimir B. Birman,<sup>c</sup> Brian B. Hasinoff<sup>b</sup> and Gary I. Dmitrienko<sup>\*a</sup>

<sup>5</sup> Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x

The synthesis of *N*-cyanobenzo[*b*]carbazoloquinone **4**, an isosteric-isoelectronic analogue of prekinamycin, is described. Cytotoxicity studies with K562 human leukemia cells reveal that the cyanamide analogue has a bioactivity profile similar to that of prekinamycin. These results indicate that  
 10 the diazo functionality may not be an absolute requirement for bioactivity.


### Introduction

The kinamycins **1** (Figure 1) are bacterial metabolites isolated from the soil bacterium *Streptomyces murayamaensis* sp. nov. Hata *et al.* by Omura and co-workers.<sup>1-5</sup> The Omura group proposed that kinamycins A, B, C and D were derivatives of *N*-cyanobenzo[*b*]tetrahydrocarbazole **2a-d** and reported that they possessed antitumour and antibacterial activity. Based on their synthetic efforts in this area, the Echevarren group cast some doubt on the validity of the structural assignment to the  
 20 kinamycins.<sup>6</sup> Later, our laboratory<sup>7</sup> and that of Gould<sup>8</sup> established the kinamycins as diazobenzo[*b*]tetrahydrofluorenes **1**, through synthetic, spectroscopic and single crystal X ray crystallographic studies.

30 Kinamycin C was reported to exhibit a significant survival effect at 0.1 mg/kg dosage i.p. in a mouse model of EHRlich ascites carcinoma and at 1.0 mg/kg in a mouse model of sarcoma-180.<sup>2</sup> Later, screening of kinamycin C versus the NIH panel of 60 cancer cell lines revealed potent in vitro cytotoxicity in the low to  
 35 submicromolar IC<sub>50</sub> range.<sup>9</sup> The more recent report by He *et al.*<sup>10</sup> of the very high cytotoxicity (nM to pM IC<sub>50</sub> range) and DNA damaging activity of the lomaiviticins, which are glycosylated dimeric analogues of the kinamycins, has stimulated still more interest in the MOA of this class of antitumor antibiotics.<sup>11</sup> The  
 40 fact that the kinamycins incorporate a paraquinone functionality that is present in other anticancer agents (e.g. doxorubicin and daunorubicin<sup>12,13</sup>) has raised the possibility of a similarity in MOA that might involve intercalation of the quinone in dsDNA followed by bioreductive activation and DNA cleavage.

45 On the other hand, the presence of the relatively rare diazo functionality in the kinamycins raises other possibilities for the MOA. Evidence to indicate that the diazo group in these compounds is rather special can be found retrospectively by examination of the results of chemical studies reported by the  
 50 Omura group, that were carried out at a time when the kinamycins were believed to be *N*-cyanobenzo[*b*]carbazoles and not diazobenzo[*b*]fluorenes. For example, the kinamycins were found to be stable to a number of acidic conditions such as 0.1 N HCl/methanol at room temperature<sup>2</sup> and *p*-toluene sulfonic acid  
 55 in refluxing acetone solution<sup>3</sup> that would be expected to lead to C-protonation and decomposition of typical diazo groups.<sup>14</sup> Furthermore, they were reported to be unstable under alkaline conditions. This property of being stable to acid but unstable to base is contrary to the known behaviour of diazo groups that are  
 60 typically generated under basic conditions and decomposed under acidic conditions.<sup>14</sup> On the other hand such behaviour is typical of aryl diazonium ions that are generated and stable under acidic conditions but are susceptible to decomposition under alkaline conditions.<sup>15</sup>


65 Several research groups have attempted to elucidate the reactivity of the diazo moiety in the context of biological activity.




**Figure 1:** Representative members of the kinamycins and lomaiviticins.

The structural novelty of the kinamycins has created interest in their mode of action (MOA), primarily in the context of their potential as anticancer reagents. The first indications of anticancer potential came from observations by the Omura group.

Jeberatnam and Arya demonstrated the DNA cleaving ability of the model compound 9-diazo fluorene under oxidizing conditions with  $\text{Cu}(\text{OAc})_2$ .<sup>16</sup> Our laboratory has shown previously that the diazo group of isoprekinamycin (**5**) is diazonium-like and hence should be activated toward attack by nucleophiles at the terminal nitrogen of the diazo group.<sup>17</sup> We suggested that nucleophilic addition followed by homolysis generates a reactive radical, a reaction typical of aryl diazonium ions.<sup>15</sup>



This reactivity is influenced by intramolecular H-bonding that enhances the diazonium ion character of the diazo group in isoprekinamycin and likewise in the kinamycins as indicated in Scheme 1.



**Scheme 1:** Possible interaction of kinamycin F (**1e**) with a biological nucleophile, potentially leading to cytotoxic events.


We also pointed out that the electron affinity (EA) is enhanced by the same H-bonding interactions, potentially enhancing the ability of such systems to undergo activation by electron transfer processes in vivo.

Later, Feldman and Eastman studied prekinamycin derivatives in radical reactions with AIBN/*(n*-butyl)<sub>3</sub>SnH and suggested that the observed chemistry was analogous to a possible electron reduction to the semiquinone to afford, after nitrogen expulsion, an  $\text{sp}^2$  radical **7** (Figure 2) that might be implicated in DNA damage via a number of potential mechanistic pathways.<sup>18,19</sup> It was further postulated that an electrophilic *o*-quinone methide **8** was also generated under the same reducing conditions and might be trapped with biological nucleophiles as part of the MOA of the kinamycins.

More recently our focus has turned towards biological studies employing protein and cell culture techniques. We have demonstrated that kinamycins A and C (**1a**, **1c**) are inhibitors, but not poisons, of topoisomerase II $\alpha$  and are potent cell growth inhibitors.<sup>20</sup> Furthermore, we have also shown that kinamycin F (**1e**), the deacetylated form of the kinamycins, is able to cleave DNA weakly on its own with increased cleavage observed in the presence of glutathione, albeit slowly under either condition.<sup>21</sup> Isoprekinamycin (**5**), recently synthesized in our laboratory, was shown to cause significant growth inhibitory effects on CHO and K562 cells.<sup>22</sup>

In a series of studies using DNA-cleavage based assays, Melander and co-workers have suggested a two electron reduction of the quinone to the hydroquinone from which arise two potential pathways for DNA cleavage.<sup>23-25</sup> The first pathway invokes (presumably with protonation occurring beforehand) a nucleophilic attack at the terminal nitrogen of the diazo moiety,

furnishing a radical **9** which then can damage DNA. The second pathway involves protonation and subsequent loss of  $\text{N}_2$ , providing the *o*-quinone methide **10** which may serve as a DNA alkylating agent.




**Figure 2:** Possible reactive intermediates.

Skibo and co-workers have carried out physical organic chemistry experiments aimed at identifying a possible MOA of prekinamycin.<sup>26</sup> Prekinamycin and a number of analogues with the diazo carbon atom enriched with <sup>13</sup>C were prepared and subjected to catalytic hydrogenation to mimic a two electron reduction that might occur in vivo. Skibo suggests that their observations are consistent with the formation of an *o*-quinone methide intermediate **11** upon a two electron reductive dediazonation of prekinamycin. Furthermore, it was suggested that prekinamycin analogues that favour the *ortho*-quinone methide tautomer **11** over the quinone tautomer **12** are more likely to act as electrophiles with DNA bases as nucleophilic partners in conjugate addition reactions. Numerous examples are known of quinone methides alkylating DNA.<sup>27</sup> The notion that kinamycins may generate quinone methides which may then go on to alkylate DNA has been known for some time,<sup>28</sup> but still remains speculative.

Herzon and coworkers have recently described the total synthesis of (-)-kinamycin F<sup>29</sup> and (-)-lomaiviticin aglycon.<sup>30</sup> Subsequent studies using a *p*MB ether substituent at the C4 position of the D-ring was employed in "biological-like" conditions in efforts to gain insight into a MOA.<sup>31</sup> When the analogue was subjected to mildly reducing conditions, an *o*-quinone methide was generated and subsequently underwent elimination of the *p*MB-alcohol to generate the corresponding acyl-fulvene **13**. This acyl-fulvene underwent a 1,6-addition with methanol as the nucleophile, furnishing the methyl ether. Subsequent bioactivity studies (LC<sub>50</sub>) showed that the C4 *p*MB ether analogue was more active than the

analogue that lacked such a group at C4. Acyl-fulvenes may indeed serve as cytotoxic agents but the structural dissimilarity of the compound used to generate **13** to that of the kinamycins suggests alternative MOAs. A very recent report from the Herzon group concludes that, in the case of the lomaiviticins, the potent cytotoxicity results from double strand cleavage of DNA that arises via a vinyl radical formed by a process analogous to that shown in Scheme 1 above.<sup>32</sup>

Our most recent studies have shown that kinamycin F selectively downregulates cyclin D3 in K562 leukemia cells at the transcription level and suggest that the kinamycins may not function simply by damaging DNA but might have a specific biological target associated with the induction of apoptosis.<sup>33</sup> This study was the first to suggest a possible alternative MOA of the kinamycins that does not necessarily involve DNA cleavage. These observations have led us to consider the possibility that at least one of the modes of action of the kinamycins may involve a complementary fit to a specific biological receptor rather than the intrinsic chemical reactivity of the diazo moiety. This could conceivably be tested by abrogating the potential chemical reactivity of the diazo group while still keeping the overall size and electronic distribution intact. An isosteric-isoelectronic replacement that would also afford the vinylogous resonance of the lone pair at C11 with the quinone moiety would be the ideal candidate. All of these attributes are conveniently found within the *N*-cyano functionality as an isosteric-isoelectronic replacement of the diazo group (Figure 3) and that bioactivity of the kinamycins may be approached from this yet to-be-addressed perspective. An initial assessment of the potential reactivity of **3** and **4** could be easily approached through theoretical calculations that might suggest an alternative MOA.



**Figure 3:** Prekinamycin **3** and the corresponding cyanamide analogue of prekinamycin **4**.

Replacing the diazo group with the cyanamide group would permit insight into the diazo group's role, if any, in the biological activity of the kinamycins. Thus, the primary motivation for the synthesis of **4** was to initiate biological studies not only to assess the importance of the diazo group, but also to evaluate benzo[*b*]carbazoloquinones in general which may be helpful in identifying the pharmacophore(s) responsible for the biological properties of the kinamycins and lomaiviticins. Ultimately, this information might facilitate drug design towards potential therapeutic agents.


## Results and discussion

### Theoretical studies


Quantum chemical calculations were undertaken on **4** and **3** at the DFT B3LYP 6-31 G(d) level of theory. Figure 4 illustrates the respective HOMOs and LUMOs of **4** and **3** and their

corresponding energy levels. We have found that the HOMO of cyanamide **4** is predicted to be 9.9 kcal·mol<sup>-1</sup> lower in energy than that of prekinamycin (**3**). As well, inspection of the LUMOs reveals that the LUMO of **4** is 4.8 kcal·mol<sup>-1</sup> lower in energy than that of **3**. In general, it is assumed that the EA is approximated by the negative reciprocal of a molecule's LUMO energy.<sup>34</sup> From this perspective, **4** would be a better electron acceptor owing to its lower energy LUMO and hence higher EA. The Gibbs free energy was retrieved for **4** (-1102.150580 a.u.) and for **3** (-1102.130649 a.u.), indicating that the cyanamide analogue is thermodynamically more stable than prekinamycin by 12.5 kcal·mol<sup>-1</sup>. These electronic properties suggest that there may be a difference by which these compounds elicit their MOA.

In order to probe the electronic differences between **4** and **3** further, an electrostatic potential energy (ESP)<sup>35</sup> surface for both **4** and **3** was generated. Figure 5 displays the ESP surface of **4** and **3**, and for the most part, the gross molecular electron distribution is relatively similar with a few key differences.



**Figure 4:** The HOMO, LUMO and their corresponding energy levels (eigenvalues) of cyanamide **4** and prekinamycin **3** generated at the DFT B3LYP 6-31 G(d) level of theory (1 a.u. = 627.5095 kcal mol<sup>-1</sup>).




**Figure 5:** The electrostatic potential energy (ESP) surfaces of **4** and **3** generated at the DFT B3LYP 6-31 G(d) level of theory (isoval 0.0004) and range from ±30.8 kcal·mol<sup>-1</sup> for **4** and ±26.3 kcal·mol<sup>-1</sup> for **3**. Regions coloured red indicate negative ESP values and regions coloured blue indicate positive values of the ESP with green being zero ESP.

The terminal nitrogen of the cyano moiety of **4** possesses more electron density than that of the terminal nitrogen of the diazo



group of **3** and intuitively, one would not expect the terminal nitrogen of the cyanamide group to be electrophilic. The lower electron density found at the terminal nitrogen of the diazo group of **3** fits well with the previous observations from this laboratory of the electrophilic character of the diazo group of the kinamycins.<sup>17, 22, 36</sup> Also, the phenolic oxygens of prekinamycin display more electron density and, hence, more partial negative charge than that of the cyanamide analogue. This is a consequence of the increase in hydrogen bonding to the quinoid oxygens of the B-ring in **3** resulting from the greater need to delocalize partial negative charge from carbon to oxygen in **3** as compared to the delocalization of partial negative charge from nitrogen to oxygen in **4**. The bond lengths in Figure 6 clearly support the notion of stronger H-bonding to the quinoid oxygens in **3** than that of **4**.



**Figure 6:** Bond lengths (Å) as observed in the minimized structures of **4** and **3** obtained at the DFT B3LYP 6-31 G(d) level of theory.


Overall, comparison of the calculated structures of **3** and **4** reveal similar spatial properties with small structural differences just described. Taken together, this would suggest that **3** and **4** may bind to the same receptor but do so with different affinities. An alternative explanation is that **3** and **4** may have different biological targets altogether. Biological testing of **3** and **4** under identical conditions would allow insight into these questions. To this end, the synthesis of the cyanamide analogue **4** was accomplished. Subsequent biological studies on the analogue **4**, prekinamycin, kinamycin F and an earlier synthetic intermediate were performed and are described in the following sections.

### Synthesis

The synthesis of **4** (Scheme 2) began with commercially available 1,5-dihydroxynaphthalene (**14**) which was protected as the *O*-methylated derivative (not shown).<sup>37</sup> Using procedures reported by Rapoport,<sup>38</sup> the formyl group was installed under Vilsmeier-Haack conditions and a subsequent Baeyer-Villiger oxidation provided formate **15** in 84% over 3 steps. Modifications<sup>39,40</sup> to the Baeyer-Villiger oxidation conditions failed to increase either the purity or yield of the formate. Methanolysis, regioselective bromination and *O*-methylation furnished the trimethoxy-bromonaphthalene **16** in 49% yield over six steps and provided the key intermediate for the impending Buchwald-Hartwig cross-coupling.

Coupling of **16** with benzophenone imine (**17**) as described by Buchwald<sup>41</sup> proceeded uneventfully and after hydrogenolysis, gave the requisite naphthylamine **18** in 78% yield over two steps. Condensation of **18** with the substituted cyclohexanedione **19** afforded anilino ketone **20** in 86% yield. Subsequent oxidative ring closure with palladium acetate using a modification of known procedures<sup>42,43</sup> provided the tetracycle, the benzo[*b*]tetrahydrocarbazole **21**. Annulation typically gave yields of 27-36%. Several attempts were made to increase the yields by

varying the time, temperature and the amount of oxidant. It was found that two equivalents of palladium acetate provided the best yields at 46-51%. *N*-Cyanation using phenyl cyanate<sup>44</sup> and subsequent oxidation with CAN provided quinone **22** in 94% yield over 2 steps. Silylation<sup>45</sup> of **22** using TBDMSOTf in dichloromethane provided the silyl enol ether **23** in 35% yield. Aromatization with DDQ in benzene and subsequent global deprotection with BBr<sub>3</sub> furnished the target **4** in a 30% yield (2 steps) with an overall yield of 1.6% over fifteen steps.



**Scheme 2:** Synthesis of *N*-cyanobenzo[*b*]carbazoloquinone **4**.

### Biological studies

The results from the testing of the growth inhibition of K562 cells (an erythroleukemic cell line) by two cyanamide analogues (**4**, **22**) prepared in the present study as well as by prekinamycin (**3**) and kinamycin F (**1e**) are shown in Table 1. The details of the cellular inhibition assay as well as the preparation of kinamycin F have been described previously.<sup>21</sup> The total synthesis of prekinamycin has been reported elsewhere.<sup>46</sup>


**Table 1:** The growth inhibition of K562 cells (IC<sub>50</sub> μM)\* for selected *N*-cyanobenzo[*b*]carbazoloquinones and diazobenzo[*b*]fluorenequinones.

IC <sub>50</sub> (μM)			
<b>22</b>	<b>4</b>	<b>3</b>	<b>1e</b>
46.6 ± 1.5	13.8 ± 4.4	13.5 ± 0.9	0.56 ± 0.12

\*Each IC<sub>50</sub> value is the mean of three experiments performed on three separate days.

Inspection of Table 1 reveals that kinamycin F (**1e**) is the most active compound with an IC<sub>50</sub> of 0.56 ± 0.12 μM. The cyanamide compound **22**, an earlier synthetic precursor of **4**, is the least bioactive with an IC<sub>50</sub> of 46.6 ± 1.5 μM. We were interested in

the biological testing of **22** as it presented as a crude monomeric model for the lomaiviticins. Further inspection of Table 1 shows that prekinamycin has an  $IC_{50}$  of  $13.5 \pm 0.9 \mu\text{M}$  and the cyanamide analogue has an  $IC_{50}$  of  $13.8 \pm 4.4 \mu\text{M}$ . The fact suggest that **4** and **3** possess comparable biological activity raises the question of what role the diazo function has with respect to mechanism of action and what the putative intracellular target(s) might be. These results have obvious implications in regard to the design of kinamycin analogues as well. We have suggested that the cytotoxicity of kinamycin F (**1e**) is due in part to the unique conformation of the polyhydroxylated D-ring, which has been shown to increase the diazonium ion character of the diazo group.<sup>36</sup> The idea that the kinamycins may serve as biological electrophiles to generate reactive species is shown in Scheme 1. In this scenario, kinamycin F, the most bioactive form of the kinamycins, possessing an electrophilic diazo moiety, is attacked by a biological nucleophile at the terminal nitrogen, furnishing an azo adduct. Subsequently, it may be envisioned that in the biological milieu, the azo adduct, upon homolysis, produces molecular nitrogen and a reactive vinyl radical, that might lead to cell death via a number of potential pathways. On the other hand, if electron transfer is important, the lower LUMO for **4** would suggest a higher electron affinity (EA) and a greater tendency of **4** to accept an electron in a single electron transfer (SET). That is, **3** is more electrophilic but **4** has a higher electron affinity. This may suggest that compounds of the *N*-cyanocarbazole series may be more prone to the formation of free radicals including oxygen free radicals (i.e.  $S + e^- \rightarrow S\dot{J}^- + {}^3O_2 \rightarrow S + {}^3O_2\dot{J}^- \rightarrow \cdot OH, \cdot OOH$ , etc.) than are the kinamycins.




**Figure 7:** The LUMO and their corresponding energy levels (eigenvalues) of kinamycin F **1e** and its hypothetical cyanamide analogue **2e** generated at the DFT B3LYP 6-31 G(d) level (1 a.u. = 627.5095 kcal·mol<sup>-1</sup>).

To investigate this issue, further ground state quantum chemical calculations on kinamycin F (**1e**) and its hypothetical cyanamide analogue **2e** were pursued (Figure 7). It was found that the cyanamide analogue of kinamycin F (**2e**) has a lower energy LUMO (by 5.5 kcal·mol<sup>-1</sup>), while kinamycin F (**1e**) possesses a significantly larger coefficient at the terminal nitrogen than the corresponding cyanamide as shown in Figure 7. Based on computed Gibbs free energies, the cyanamide **2e** is predicted to be more stable than kinamycin F by 11.6 kcal·mol<sup>-1</sup>. Taken


together, these data parallel the same trend as found for comparisons of the electronic properties of **4** and **3**. In this context, the results presented in Table 1 and Figure 7 raise the question of which should be the more potent anti cancer agent: kinamycin F or its cyanamide congener.

It is possible that multiple interactions with various targets contribute to the activity of prekinamycin (**3**) and the cyanamide analogue **4**. These include:

1. Electron transfer to generate a radical anion which might then interact directly with DNA or first  ${}^3O_2$  leading to oxygen radicals which then go on to cleave DNA. This is possible for **4** and **3** but is more likely for **4** owing to its lower LUMO.



2. Reaction with biological nucleophiles (DNA, protein). This applies for **3**.



3. Non-covalent binding to a biological receptor which is possible for both **4** and **3**. In the case of kinamycin F, a recent study involving this laboratory has revealed that kinamycin F may be specifically targeting a protein involved in transcription of cyclin D3, one of a group of proteins involved in the cell cycle. The contribution of such an interaction to the overall MOA of kinamycin F is unlikely to be the consequence of a non-selective DNA cleavage event.<sup>33</sup> A non-covalent or possibly a covalent binding to such a protein target by kinamycin F or one of its metabolites might explain the cytotoxicity since the diminution of cyclin D3 levels is known to induce apoptosis (programmed cell death). It is not yet known if similar effects on cyclin D3 levels are induced by prekinamycin, isoprekinamycin or the lomaiviticins.

One interpretation of the comparable cytotoxicity of **4** and **3** is that for **4**, the electron transfer MOA makes a better contribution to the cytotoxicity effect, whereas for **3** the reaction with biological nucleophiles may be more important. Another interesting observation is the very low activity of the ketone **22**. In the kinamycin series, the dimeric analogues called the lomaiviticins **6** possess such a keto group and are very active in DNA cleavage experiments under reducing conditions and are highly cytotoxic to cancer cells; more so than the monomeric kinamycins that lack the keto group. It is not clear, however, if the *O*-methyl group might play a role in the low activity of **22**. This speculation is borne out by Herzon's recent observations in which kinamycin analogues bearing methoxy substituents displayed cytotoxicity that was substantially lower than values obtained from the corresponding analogues bearing hydroxyl

groups.<sup>31</sup>

## Conclusions

This study has provided some insight into the similarity and differences between the *N*-cyanobenzo[*b*]carbazole-based structure originally assigned to the kinamycins<sup>1</sup> and the corrected (diazobenzo[*b*]fluorene-based) structure assigned more recently.<sup>6, 7</sup> We conclude that there is sufficient similarity between compounds possessing these core structures in regard to electronic structure and cell growth inhibition of K562 leukemia cells to warrant further study of *N*-cyanobenzo[*b*]carbazole-type analogues of the kinamycins. Synthetic efforts aimed at accessing such analogues are in progress.

## Acknowledgments

Mrs. Valerie Goodfellow, Dr. Nan Chen and Dr. Otunola Adedayo are thanked for generating the sample of kinamycin F used in this study. This work was supported by a Discovery grant from the Natural Sciences and Engineering Research Council of Canada (to G. I. D.), the Canadian Institutes of Health Research and a Canada Research Chair in Drug Development grants (to B.B.H.) and an American Chemical Society Petroleum Research Fund grant (to V.B.B.). An Ontario Graduate Scholarship (to G.L.A.) is gratefully acknowledged.

## Notes and references

\* corresponding author

<sup>25</sup> <sup>a</sup> Department of Chemistry, University of Waterloo, 200 University Ave. West, Waterloo, Ontario, Canada, N2L 3G1. Fax: 1-519-746-0435; Tel: 1-519-888-4567 ext. 84642; E-mail: dmitrien@uwaterloo.ca

<sup>b</sup> Faculty of Pharmacy, Apotex Centre, University of Manitoba, 750 McDermot Ave., Winnipeg, Manitoba, Canada, R3E 0T5. Fax: 1-204-474-7617; Tel: 1-204-474-8325; E-mail: B\_Hasinoff@umanitoba.ca

<sup>30</sup> <sup>c</sup> Department of Chemistry, Washington University, 750 Campus Box 1134, One Brookings Drive, St Louis, Missouri, U.S.A., 63130. E-mail: birman@wustl.edu

<sup>35</sup> † Electronic Supplementary Information (ESI) available: computational method, cell culture and growth inhibition assay details, experimental and synthetic procedures, full characterization data, <sup>1</sup>H and <sup>13</sup>C NMR spectra. See DOI: 10.1039/b000000x/

1. S. Ito, T. Matsuya, S. Omura, M. Otani and A. Nakagawa, *J. Antibiotics*, 1970, **23**, 315-317.
2. T. Hata, S. Omura, Y. Iwai, A. Nakagawa and M. Otani, *J. Antibiotics*, 1971, **24**, 353-359.
3. S. Omura, A. Nakagawa, H. Yamada, T. Hata, A. Furusaki and T. Watanabe, *Chem. Pharm. Bull.*, 1971, **19**, 2428-2430.
4. A. Furusaki, T. Watanabe, T. Hata, S. Omura, A. Nakagawa and M. Matsui, *Isr. J. Chem.*, 1972, **10**, 173-187.
5. S. Omura, A. Nakagawa, H. Yamada, T. Hata, A. Furusaki and T. Watanabe, *Chem. Pharm. Bull.*, 1973, **21**, 931-940.
6. A. M. Echevarren, N. Tamayo, M. C. Paredes, *Tetrahedron Lett.*, 1993, **34**, 4713.
7. S. Mithani, G. Weeratunga, N. J. Taylor and G. I. Dmitrienko, *J. Am. Chem. Soc.*, 1994, **116**, 2209-2210.
8. S. J. Gould, N. Tamayo, C. R. Melville and M. C. Cone, *J. Am. Chem. Soc.*, 1994, **116**, 2207-2208.
9. See NCII38425 at <http://dtp.nci.nih.gov>

10. H. He, W. D. Ding, V. S. Bernan, A. D. Richardson, C. M. Ireland, M. Greenstein, G. A. Ellestad and G. T. Carter, *J. Am. Chem. Soc.*, 2001, **123**, 5362-5363.
11. S. B. Herzon and C. M. Woo, *Nat. Prod. Rep.*, 2012, **29**, 87-118.
12. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo and L. Gianni, *Pharmacol. Rev.*, 2004, **56**, 185-229.
13. D. A. Gewirtz, *Biochem. Pharmacol.*, 1999, **57**, 727-741.
14. M. Regitz and G. Maas, *Diazo compounds: Properties and Synthesis*, Academic Press, Orlando, 1986, p. 96.
15. H. Zollinger, *Accounts Chem. Res.*, 1973, **6**, 335-341.
16. D. P. Arya and D. J. Jebaratnam, *J. Org. Chem.*, 1995, **60**, 3268-3269.
17. R. S. Laufer and G. I. Dmitrienko, *J. Am. Chem. Soc.*, 2002, **124**, 1854-1855.
18. K. S. Feldman and K. J. Eastman, *J. Am. Chem. Soc.*, 2006, **128**, 12562-12573.
19. K. S. Feldman and K. J. Eastman, *J. Am. Chem. Soc.*, 2005, **127**, 15344-15345.
20. B. B. Hasinoff, X. Wu, J. C. Yalowich, V. Goodfellow, R. S. Laufer, O. Adedayo and G. I. Dmitrienko, *Anti-Cancer Drugs*, 2006, **17**, 825-837.
21. K. A. O'Hara, X. Wu, D. Patel, H. Liang, J. C. Yalowich, N. Chen, V. Goodfellow, O. Adedayo, G. I. Dmitrienko and B. B. Hasinoff, *Free Radical Bio. Med.*, 2007, **43**, 1132-1144.
22. W. Liu, M. Buck, N. Chen, M. Shang, N. J. Taylor, J. Asoud, X. Wu, B. B. Hasinoff and G. I. Dmitrienko, *Org. Lett.*, 2007, **9**, 2915-2918.
23. W. Zeng, T.E. Ballard, A.G. Tkachenko, V.A. Burns, D.L. Feldheim and C. Melander, *Bioorg. Med. Chem. Lett.*, 2006, **16**, 5148-5151.
24. T.E. Ballard and C. Melander, *Tetrahedron Lett.*, 2008, **49**, 3157-3161.
25. C. L. Heinecke and C. Melander, *Tetrahedron Lett.*, 2010, **51**, 1455-1458.
26. O. Khdour and E. B. Skibo, *Org. Biomol. Chem.*, 2009, **7**, 2140-2154.
27. S. E. Rokita, *Quinone methides*, Wiley, Hoboken, N.J., 2009, p. 431.
28. H. W. Moore, *Science*, 1977, **197**, 527-532.
29. C. M. Woo, L. Lu, S. L. Gholap, D. R. Smith and S. B. Herzon, *J. Am. Chem. Soc.*, 2010, **132**, 2540-2541.
30. S. B. Herzon, L. Lu, C. M. Woo and S. L. Gholap, *J. Am. Chem. Soc.*, 2011, **133**, 7260-7263.
31. S. P. Mulcahy, C. M. Woo, W. D. Ding, G. A. Ellestad and S. B. Herzon, *Chem. Sci.*, 2012, **3**, 1070-1074.
32. L. C. Colis, C. M. Woo, D. C. Hegan, Z. Li, P. M. Glazer, S. B. Herzon, 2014, *Nature Chemistry*; published on-line May 11, 2014 <http://dx.doi.org/10.1038/nchem.1944>
33. K. A. O'Hara, G. I. Dmitrienko and B. B. Hasinoff, *Chem.-Biol. Interact.*, 2010, **184**, 396-402.
34. A. Szabo and N. S. Ostlund, *Modern Quantum Chemistry: Introduction to Advanced Electronic Structure Theory*, McGraw-Hill, New York, 1989, p. 127.
35. E. V. Anslyn and D. A. Dougherty, *Modern Physical Organic Chemistry*, University Science, Sausalito, Calif., 2006, p. 14-15.

- 
36. N. Chen, M. B. Carriere, R. S. Laufer, N. J. Taylor and G. I. Dmitrienko, *Org. Lett.*, 2008, **10**, 381-384.
37. T. W. Greene and P. G. M. Wuts, *Protective Groups in Organic Synthesis*, Wiley, New York, 1999, p. 23.
- 5 38. R. L. Hannan, R. B. Barber and H. Rapoport, *J. Org. Chem.*, 1979, **44**, 2153-2158.
39. R. W. Franck and R. B. Gupta, *J. Org. Chem.*, 1985, **50**, 4632-4635.
40. C. Bolchi, P. Catalano, L. Fumagalli, M. Gobbi, M. Pallavicini, A. Pedretti, L. Villa, G. Vistoli and E. Valoti, *Bioorgan. Med.*
- 10 *Chem.*, 2004, **12**, 4937-4951.
41. J. P. Wolfe, J. Ahman, J. P. Sadighi, R. A. Singer and S. L. Buchwald, *Tetrahedron Lett.*, 1997, **38**, 6367-6370.
42. B. Akermark, L. Ebersson, E. Jonsson and E. Pettersson, *J. Org. Chem.*, 1975, **40**, 1365-1367.
- 15 43. H. J. Knolker and K. R. Reddy, *Chem. Rev.*, 2002, **102**, 4303-4427.
44. R. E. Murray and G. Zweifel, *Synthesis*, 1980, 150-151.
45. L. N. Mander and S. P. Sethi, *Tetrahedron Lett.*, 1984, **25**, 5953-5956.
46. V. B. Birman, Z. F. Zhao and L. Guo, *Org. Lett.*, 2007, **9**, 1223-1225.

20